Common grade 3 or 4 adverse events included hypertriglyceridaemia ( 38 [ 14 % ] ) , fatigue ( 28 [ 10 % ] ) , hypertension ( 22 [ 8 % ] ) , and diarrhoea ( 20 [ 7 % ] ) in the dovitinib group , and hypertension ( 47 [ 17 % ] ) , fatigue ( 24 [ 8 % ] ) , dyspnoea ( 21 [ 7 % ] ) , and palmar-plantar erythrodysaesthesia ( 18 [ 6 % ] ) in the sorafenib group .